Teles AG Informationstechnologien (TLIK) AI Stock Analysis

• Market Cap: €1.62M
• Dividend Yield: N/A
• Average Volume (3M): 390.00
• Price to Earnings (P/E): ―
• Beta (1Y): -72.80
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: DE
• Employees: 2
• Sector: Technology
• Sector Strength: 88
• Industry: Medical - Distribution
• EPS (TTM): N/A
• Shares Outstanding: 6,233,418
• 10 Day Avg. Volume: 501
• 30 Day Avg. Volume: 390
• PEG Ratio: 0.08
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 5.45
• P/FCF Ratio: -2.55
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 38 Underperform
• Price Target: €0.21 ▼(-37.58% Downside)
• Action: N/A Date: 01/14/26
• Date: Action: N/A 01/14/26

The score is held near the floor primarily by severely weakened financial performance (collapsed revenue, very large losses, ongoing cash burn, and a weakened balance sheet with higher debt and zero reported equity). Technicals add further pressure with price trading below key moving averages and negative MACD, while valuation metrics are not supportive due to a negative P/E and no dividend data.

Positive Factors

High gross margin

High gross profit relative to revenue indicates the company’s core offerings retain strong unit economics. Over a multi-month horizon, such margins give room to absorb fixed costs, speed recovery of operating profits if sales stabilize, and improve cash conversion as volumes recover.

Negative Factors

Collapsed revenue

A ~99% year-over-year revenue collapse is a severe structural impairment: it destroys scale, undermines customer and market relevance, and prevents effective absorption of fixed costs. Over months this materially raises the likelihood of prolonged losses and constrains recovery pathways.

Teles AG Informationstechnologien Business Overview & Revenue Model

Company Description

Arzneiwerk AG VIDA engages in the supply of pharmaceuticals for newly developed or rare medicines in Europe. The company was formerly known as TELES Aktiengesellschaft and changed its name to Arzneiwerk AG VIDA in July 2024. The company was incorp...

Read more

Arzneiwerk AG VIDA engages in the supply of pharmaceuticals for newly developed or rare medicines in Europe. The company was formerly known as TELES Aktiengesellschaft and changed its name to Arzneiwerk AG VIDA in July 2024. The company was incorp...

How the Company Makes Money

null...

Teles AG Informationstechnologien Financial Statement Overview

Breakdown	TTM	Dec 2024	Mar 2024	Mar 2022	Dec 2020	Dec 2019
Income Statement
Total Revenue	-44.69M	657.55K	1.67M	2.67M	2.82M	4.16M
Gross Profit	-2.05M	657.47K	1.45M	2.17M	2.30M	2.17M
EBITDA	-1.06M	-661.20K	―	-237.78K	922.87K	2.16M
Net Income	-442.86K	-835.24K	-1.89M	-267.51K	824.51K	3.87M
Balance Sheet
Total Assets	4.61M	4.17M	3.30M	2.85M	1.18M	2.78M
Cash, Cash Equivalents and Short-Term Investments	5.18K	125.52K	82.11K	391.22K	751.55K	13.32K
Total Debt	0.00	636.00K	125.00K	0.00	0.00	173.00K
Total Liabilities	4.61M	4.17M	3.30M	1.24M	1.16M	2.78M
Stockholders Equity	0.00	0.00	0.00	1.61M	13.30K	―
Cash Flow
Free Cash Flow	-1.79M	-1.41M	-1.09M	-330.33K	-999.61K	―
Operating Cash Flow	-1.85M	-1.41M	-1.09M	-280.65K	-986.42K	―
Investing Cash Flow	-217.22K	-6.72K	0.00	-79.68K	-13.19K	0.00
Financing Cash Flow	1.19M	1.45M	1.13M	0.00	1.74M	600.00K

Teles AG Informationstechnologien Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CEK	69 Neutral	€86.98M	6.51	26.52%	1.50%	88.29%	245.35%
D6H	62 Neutral	€625.66M	24.19	13.51%	1.43%	7.30%	-15.88%
Sector *	61 Neutral	$37.18B	12.37	-10.20%	1.83%	8.50%	-7.62%
TMV	61 Neutral	€659.89M	8.03	96.15%	―	11.14%	0.92%
TLIK	38 Underperform	€1.62M	―	―	―	―	―